Incyte Corp.

NASDAQ:INCY   10:35:11 AM EDT
78.66
-0.64 (-0.81%)
Products

Incyte Announces Outcome Of FDA ODAC Meeting Reviewing Retifanlimab As A Treatment For Patients With Squamous Cell Carcinoma Of The Anal Canal (Scac)

Published: 06/24/2021 20:10 GMT
Incyte Corp. (INCY) - Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (odac) Meeting Reviewing Retifanlimab As a Treatment for Patients With Squamous Cell Carcinoma of the Anal Canal (scac).
Incyte - Odac Voted 13-4 That Regulatory Decision on Retifanlimab Should Be Deferred Until Further Data Are Available From Clinical Trial Pod1um-303.